Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Dendritic cells (DCs) are key regulators of immune responses that operate at the interface between innate and adaptive immunity, and defects in DC functions contribute to the pathogenesis of a variety of disorders. For instance, cancer evolves in the context of limited DC activity, and some autoimmune diseases are initiated by DC-dependent antigen presentation. Thus, correcting aberrant DC functions stands out as a promising therapeutic paradigm for a variety of diseases, as demonstrated by an abundant preclinical and clinical literature accumulating over the past two decades. However, the therapeutic potential of DC-targeting approaches remains to be fully exploited in the clinic. Here, we discuss the unique features of DCs that underlie the high therapeutic potential of DC-targeting strategies and critically analyze the obstacles that have prevented the full realization of this promising paradigm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129 · cited 1×
“This can be achieved by the following: (1) culturing ex vivo DCs derived from patients with tumor antigens and activation stimuli and subsequently transferring the activated DCs back into patients or (2) inducing tumor antigen uptake by DCs directly in vivo (7, 97) The first proof-of-principle studies exploring DC imm…”
BackgroundImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804 · cited 1×
“The first clinical study of a DC anti-cancer vaccine in B-cell lymphoma patients was reported byHsu and colleagues in Nature Medicine in 1996 (99).”
BackgroundMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Human dendritic cell subsets: an update
Collin, M., & Bigley, V. (2018) · Immunology · doi:10.1111/imm.12888 · Cited by 1,301
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.025 · Cited by 933 · cited 1×
“Finally, the functionality of tolDCs is connected with their metabolic activity, such as lipid accumulation, enhanced oxidative phosphorylation, fatty acid oxidation, and modulation of glycolysis (39, 47).”
BackgroundCross-Presentation, Dendritic Cells, Tolerance and Immunity
Heath, W. R., & Carbone, F. R. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.47 · Cited by 882 · cited 4×
“state with low expression of MHC molecules and costimulatory molecules, such as CD80 and CD86 (9, 32, 33).”
BackgroundInfluentialDendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2376 · Cited by 838 · cited 1×
“However, the differentiation of DCs in the TME is often mediated by the interplay between IL-6 and macrophage colony-stimulating factor (M-CSF), resulting in the recruitment and accumulation of functionally deficient and frequently iDCs unable to induce the proliferation of tumor-specific CD4 and CD8 T cells (65, 66).”
BackgroundChao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Böttcher, J. P., & Reis e Sousa, C. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.09.001 · Cited by 607
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
The clearance of dying cells: table for two
Green, D. R., Oguin, T. H., & Martinez, J. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.172 · Cited by 314
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968434 · Cited by 200
Self-citationTranscriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance
Soto-Nieves, N., Puga, I., Abe, B. T., Bandyopadhyay, S., Baine, I., Rao, A., & Macian, F. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082731 · Cited by 86
Cited by
NF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
Kuo, C.-L., Ponneri Babuharisankar, A., Lin, Y.-C., Lien, H.-W., Lo, Y. K., Chou, H.-Y., Tangeda, V., Cheng, L.-C., Cheng, A. N., & Lee, A. Y.-L. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00859-2 · Cited by 351
Metadata
- Authors
- Fucikova, J., Palova-Jelinkova, L., Bartunkova, J., & Spisek, R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-10-29
- Volume
- 10
- Pages
- 2393-2393
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2982392853
- Cited by
- 173
- References
- 20
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.